Company
SIGA Technologies, Inc.
Headquarters: New York, NY, United States
Founded: December 28, 1995
Employees: 39
CEO: Dr. Phillip Louis Gomez III, M.D., Ph.D.
Market Cap
$456.3 Million
USD as of Jan. 1, 2025
SIGA Technologies, Inc. Categories
United States Healthcare BiotechnologyUnited States Healthcare United States Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $113.24 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $76.33 B |
| Marinomed Biotech AG | $56.13 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Detailed Description
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats. The company was incorporated in 1995 and is headquartered in New York, New York.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Financials
| Last Financial Reports Date | Dec. 31, 2023 |
| Revenue TTM | $139.9 M |
| EBITDA | $84.2 M |
| Gross Profit TTM | $105.7 M |
| Profit Margin | 48.65% |
| Operating Margin | 78.71% |
| Quarterly Revenue Growth | 925.50% |
Stocks & Indices
SIGA Technologies, Inc. has the following listings and related stock indices.
Stock: NASDAQ: SIGA wb_incandescent
Product & Services
Pharmaceutical agents
Key People
Eric A. Rose M. D. (Chairman) Phillip L. Gomez (CEO) Daniel J. Luckshire (CFO) Robin E. Abrams (General Counsel and CAO)